Clinical Trials for Mesothelioma Patients: NGR-hTNF as Single Agent Exclusion Criteria

Read about the exclusion criteria for a current clinical trial being conducted to study NGR-hTNF as a single agent in patients who have been diagnosed with mesothelioma. At this time, the study is only being conducted in Italy. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Exclusion Criteria:
Concurrent anticancer therapy

Patients may not receive any other investigational agents while on study

Clinical signs of CNS involvement

Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol

Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients

Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol

Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.